# Lisa Olson

> Lisa M. Olson, Ph.D., is a biopharmaceutical research leader who became CEO of Milan-based clinical-stage biotech Enthera Pharmaceuticals in January 2024, after years on its board and as chair of its Scientific Advisory Board. Across two decades in immunology drug discovery - 15 years at AbbVie/Abbott where she helped advance 15 molecules into the clinic including Rinvoq, plus roles at Pfizer and as Chief Scientific Officer of Magenta Therapeutics - she has built a career turning biology into medicine. At Enthera she is steering the clinical development of Ent001, a first-in-class antibody targeting the IGFBP3/TMEM219 pathway for inflammatory bowel disease and type 1 diabetes.

- **Role:** Chief Executive Officer at Enthera Pharmaceuticals
- **Organizations:** Enthera Pharmaceuticals, Magenta Therapeutics, AbbVie, Abbott Laboratories, Pfizer, Washington University School of Medicine
- **Nationality:** American
- **Education:** B.S., Iowa State University, Ph.D., University of Illinois at Urbana-Champaign, Post-doctoral cardiovascular fellowship, University of Chicago
- **Known for:** Helped advance 15 molecules into clinical development during her tenure at AbbVie, including Rinvoq (upadacitinib), Led R&D strategy as Chief Scientific Officer at Magenta Therapeutics, Rose to Vice President of Immunology Discovery and Site Head of the AbbVie Bioresearch Center

## Career timeline

- **—** — Post-doctoral cardiovascular fellowship at the University of Chicago
- **—** — Assistant Professor at Washington University School of Medicine
- **—** — Research Fellow in Inflammation and Immunology at Pfizer
- **—** — Fifteen years at AbbVie/Abbott, rising to Vice President of Immunology Discovery and Site Head of the AbbVie Bioresearch Center
- **—** — Chief Scientific Officer at Magenta Therapeutics, leading R&D strategy
- **2020** — Appointed to Enthera Pharmaceuticals' Scientific Advisory Board (later chaired it) and joined its Board of Directors
- **2024** — Appointed Chief Executive Officer of Enthera Pharmaceuticals (January)

## Achievements

- Helped advance 15 molecules into clinical development during her tenure at AbbVie, including Rinvoq (upadacitinib)
- Led R&D strategy as Chief Scientific Officer at Magenta Therapeutics
- Rose to Vice President of Immunology Discovery and Site Head of the AbbVie Bioresearch Center
- Oversaw Enthera's Ent001 Phase 1a completion and Phase 1b initiation as incoming CEO

## Latest updates

- **2024-01** — Appointed CEO of Enthera Pharmaceuticals as the company reported Ent001 Phase 1a safety results and launched a Phase 1b trial in moderately-to-severely active ulcerative colitis.

## Links

- Website: https://entherapharmaceuticals.com
- LinkedIn: https://www.linkedin.com/in/lisa-olson-5b889412

---

Profile page: https://yespress.io/lisa-olson
Published by YesPress — https://yespress.io
Last updated: 2026-06-11